ATXI: Avenue Therapeutics Inc Forward P/S Multiple

Corporate emblem and logo of Avenue Therapeutics, Inc (ATXI)

Regulatory challenges with the FDA have weakened the intellectual property patent protection of Avenue Therapeutics (ATXI). Meanwhile, an asset-light model minimizes costs, directing resources into R&D for subsequent distribution through partners. The forward price-to-sales valuation trend visualizes market expectations, where the level reflects the current magnitude. The ultimate success of the business is based on the safety of new therapies and the efficiency of engagement with medical networks.

Avenue Therapeutics, Inc. - ATXI Market Cap to Future Revenue Ratio (period 07/04/2022 - 11/17/2026)

Metric breakdowns and analytics for avenuetx.com (ATXI)

Fundamental valuation:avenuetx.com ATXI
Product sample of Avenue Therapeutics

This ratio reflects the relationship between the market value of Avenue Therapeutics (ATXI) and its expected annual revenue, allowing for an assessment of the extent to which the company's future successes are priced in. By analyzing the forward P/S of the business, an investor can compare market expectations with the efficiency of the production and clinical research outsourcing model, which minimizes capital expenditures for Avenue Therapeutics during therapy scaling.

Competitor analysis

Forward P/S Multiple BIIB (Biogen Idec)|Market Cap to Expected Sales Ratio Neurocrine Corp (NBIX)|RGC: Forward Price-to-Revenue Multiple|Forward Price to Sales AXSM (Axsome Therapeutics)|ACAD: Forward P/S Multiple|Xenon Pharmaceuticals Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio Viking Pharma|SUPN: Forward Price to Sales|Forward P/S Multiple CPRX|Forward P/S Multiple denalitherapeutics.com (DNLI)|Forward P/S Multiple HRMY (Harmony Biosciences Inc)|Market Cap to Expected Sales Ratio Biohaven (BHVN)|Amylyx Corp - Forward P/S Multiple|TRVI - Forward P/S Multiple|Praxis Precision Medicines Inc (PRAX) - Price-to-Projected Revenue Ratio|AVXL - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio CeriBell|Forward P/S Multiple Prothena Corporation plc|Price-to-Projected Revenue Ratio Alector Therapeutics (ALEC)|Annexon Inc. - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio omeros.com OMER|neurogene.com (NGNE) - Market Cap to Future Revenue Ratio|acimmune.com - Forward P/S Multiple|Voyager Therapeutics Inc (VYGR) - Forward Price-to-Revenue Multiple|Neumora Corp (NMRA) - Price-to-Projected Revenue Ratio|Scilex Holding Company, Inc. (SCLX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple TVGN|Market Cap to Future Revenue Ratio Alpha Cognition Inc. ACOG|Price-to-Projected Revenue Ratio cogrx.com (CGTX)|Market Cap to Expected Sales Ratio Inhibikase Therapeutics, Inc.|Forward P/S Multiple SAVA (Cassava Sciences Inc)|Forward P/S Multiple Assertio Holdings, Inc. ASRT|COYA - Price-to-Projected Revenue Ratio|Projected Price to Revenue Vistagen (VTGN)|OVID: Forward P/S Multiple|Market Cap to Future Revenue Ratio Acumen Pharmaceuticals Inc. (ABOS)|Forward Price-to-Revenue Multiple CRVO|Market Cap to Projected Revenue ATHE (Alterity Therapeutics)|Price-to-Projected Revenue Ratio Clene Nanomedicine (CLNN)|PEPG (PepGen) - Forward Price to Sales|Price-to-Projected Revenue Ratio Jupiter Neurosciences Inc JUNS|Forward Price to Sales RLMD|ANVS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Grace Therapeutics Inc|AIFF: Forward P/S Multiple|Market Cap to Future Revenue Ratio Klotho Neurosciences Inc (KLTO)|Price-to-Projected Revenue Ratio neurosense-tx.com|Market Cap to Future Revenue Ratio Reviva Pharmaceuticals Holdings Inc. RVPH|Price-to-Projected Revenue Ratio MetaVia Inc. (MTVA)|Market Cap to Expected Sales Ratio NeurAxis Inc|Forward P/S Multiple HSDT (heliusmedical.com)|Forward Price to Sales PASG|NEUP: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Minerva Neurosciences Inc|Athira Pharma (ATHA) - Price-to-Projected Revenue Ratio|Addex Therapeutics, Ltd. - Forward Price to Sales|ALZN (Alzamend Neuro) - Forward P/S Multiple|Market Cap to Future Revenue Ratio cyclerion.com CYCN|Forward P/S Multiple PTIX|KTTA - Market Cap to Future Revenue Ratio|Forward P/S Multiple CRGT (Cortigent, Inc.)|BrainStorm Cell Therapeutics Inc. - Price-to-Projected Revenue Ratio|Cara Therapeutics Inc. - Forward P/S Multiple|Chromocell Therapeutics (CHRO) - Forward Price-to-Revenue Multiple|ELYM: Forward P/S Multiple|Forward Price-to-Revenue Multiple Intra-Cellular Therapies Inc.|LBPH (Longboard Pharmaceuticals Inc) - Forward P/S Multiple|Marinus - Future Price to Revenue|Forward P/S Multiple NKGN|NRBO (NeuroBo Pharmaceuticals) - Forward Price to Sales|Forward P/S Multiple SAGE (Sage Therapeutics Inc)|Market Cap to Expected Sales Ratio Synaptogenix Inc. (SNPX)|TRVN - Price-to-Projected Revenue Ratio|vigilneuro.com (VIGL) - Forward Price-to-Revenue Multiple|WENA: Forward P/S Multiple|Cerevel Therapeutics, Inc. (CERE) - Forward P/S Multiple